You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 354 Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cell Therapies
354 Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML
Free

Authors

Citation

Wieduwild E, Floch AL, Garulli C, et al
354 Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0354

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.